Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 14,943 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness

NCT07053969
View directory record Official record
Conditions
Dental Implantation, Missing Teeth, Periodontitis, Adult, Mucositis
Interventions
Enamel Matrix Derivative
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers

NCT05640583
View directory record Official record
Conditions
Irritable Bowel Disease
Interventions
Hygieacare System
Device
Lead sponsor
HyGIeaCare, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 29, 2026, 4:34 AM EDT
Recruiting No phase listed Observational

Myriad™ Augmented Soft Tissue Reconstruction Registry

NCT05243966
View directory record Official record
Conditions
Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
Interventions
Myriad Matrix™ and Myriad Morcells™
Device
Lead sponsor
Aroa Biosurgery Limited
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 1 Interventional

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

NCT00486356
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, carboplatin, epirubicin hydrochloride, microarray analysis, polymorphism analysis, pharmacological study
Drug · Genetic · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 29, 2026, 4:34 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Shield Post-Approval Study Protocol

NCT06880055
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Shield Blood Test for colo-rectal cancer Screening
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
45 Years to 81 Years
Enrollment
3,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
60
States / cities
Chandler, Arizona • Gilbert, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Results available

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

NCT03006926
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
lenvatinib, pembrolizumab (200 mg)
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

NCT00663208
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 29, 2026, 4:34 AM EDT
Completed No phase listed Observational

The Microvascular Complications Study

NCT00222508
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

NCT00669825
View directory record Official record
Conditions
Celiac Disease
Interventions
ALV003, Placebo
Drug
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Oct 29, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

Improving Care for Rural Patients With Solid Tumors

NCT04916990
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Interventions
CARES Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

NCT00994110
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pasireotide (SOM230), placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 29, 2026, 4:34 AM EDT
Withdrawn Phase 1Phase 2 Interventional

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

NCT02344810
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
c-Met inhibitor AMG 337, placebo, oxaliplatin, leucovorin calcium, fluorouracil, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Early Phase 1 Interventional

Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis

NCT03268213
View directory record Official record
Conditions
Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
7 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

NCT00019760
View directory record Official record
Conditions
Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
Interventions
floxuridine, leucovorin calcium, melphalan
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 29, 2026, 4:34 AM EDT
Not listed No phase listed Observational

Gut Recovery In Patients Following Surgery

NCT05712525
View directory record Official record
Conditions
Gastrointestinal Diseases, Ileus
Interventions
G-Tech Wireless Patch System (WPS)
Diagnostic Test
Lead sponsor
G-Tech Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 29, 2026, 4:34 AM EDT
Completed No phase listed Observational

OPERA Database - Crohn's Protocol

NCT01720368
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 1 Interventional

Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer

NCT00905918
View directory record Official record
Conditions
Colorectal Cancer
Interventions
vitamin E, laboratory biomarker analysis
Dietary Supplement · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Results available

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

NCT02078882
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
abatacept
Biological
Lead sponsor
Christopher Bowlus, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 29, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)

NCT05375643
View directory record Official record
Conditions
Gastrointestinal Cancer, Hematologic Cancer, Thoracic Cancer
Interventions
SURGE
Behavioral
Lead sponsor
Nadine Jackson, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 29, 2026, 4:34 AM EDT
Completed No phase listed Observational Results available

The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment

NCT02763215
View directory record Official record
Conditions
Wilson Disease
Interventions
Standard of Care Medications
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
New Haven, Connecticut • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 29, 2026, 4:34 AM EDT
Completed Not applicable Interventional Results available

AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study

NCT03525808
View directory record Official record
Conditions
Walled Off Pancreatic Necrosis
Interventions
AXIOS
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 29, 2026, 4:34 AM EDT
Withdrawn Not applicable Interventional

Neurostimulation for the Treatment of Post-Operative Ileus

NCT00854074
View directory record Official record
Conditions
Ileus
Interventions
ElectroCore RMS-1100 Resolution Motility System™
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 29, 2026, 4:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

NCT05223218
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Melanoma
Interventions
Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Other
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 29, 2026, 4:34 AM EDT
Recruiting Phase 1 Interventional

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Interventions
TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (givastomig), durvalumab, chemotherapy
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 29, 2026, 4:34 AM EDT